Kaplan Fox Investigates Fulcrum Therapeutics Over Stock Drop

Kaplan Fox & Kilsheimer LLP, a nationally recognized law firm, has initiated an investigation into potential securities violations against Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to treat rare hematological disorders. The investigation is aimed at identifying any wrongdoing that may have affected Fulcrum Therapeutics' investors.

On June 1, 2026, Fulcrum Therapeutics announced the discontinuation of its pociredir program for the treatment of sickle cell disease (SCD). The company cited heightened FDA concerns regarding the benefit-risk profile of pociredir, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik® (tazemetostat), another PRC2 inhibitor that was withdrawn from the global market in March 2026. The FDA concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk, regardless of the specific subunit engaged. As a result, Fulcrum Therapeutics has no viable regulatory path forward for further clinical development of pociredir.

Following this news, the stock price of Fulcrum Therapeutics declined significantly. The stock closed at $6.42 per share on June 1, 2026, and dropped to $3.14 per share on June 2, 2026, marking a decline of $3.28 per share, or 51.09%.

Kaplan Fox & Kilsheimer LLP, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey, is urging Fulcrum Therapeutics investors who have suffered losses to contact the firm. The law firm, founded in 1956, has a history of prosecuting complex litigation, including securities, antitrust, and consumer protection actions. With a track record of securing some of the largest recoveries in the history of securities litigation, Kaplan Fox is well-positioned to represent investors in this case.